相关实验视频

Updated: Sep 12, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

癌症治疗中的LSD1/HDAC双抑制剂:挑战与机遇

Dan-Dan Shen¹, Hao-Qian Zhang¹, Chen-Chen Ren¹

¹Department of Obstetrics and Gynecology, Zhengzhou Key Laboratory of Endometrial Disease Prevention and Treatment Zhengzhou China, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

Bioorganic chemistry

|August 9, 2025

概括

阻断氨酸特异性脱甲基酶1 (LSD1) 和胰岛素脱甲基酶 (HDAC) 的双抑制剂在癌症治疗中表现有前途. 这些双功能药物通过协同重塑染色质结构来提供增强的抗瘤作用.

科学领域:

在瘤学瘤学.
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
药用化学医学化学

背景情况:

表观遗传调节剂,如氨酸特异性脱甲基酶1 (LSD1) 和基因素脱甲基酶 (HDAC),在癌症的发展中至关重要.
在瘤中LSD1和HDAC的过度表达驱动了通过基因组修饰的增殖和分化.
单位抑制剂面临诸如补偿信号和耐药性等挑战,限制了临床疗效.

研究的目的:

审查癌症治疗中LSD1和HDAC双抑制剂的最新进展.
突出双功能抑制剂在克服单位药物的局限性方面的潜力.
刺激这些新型治疗剂的未来研究和结构优化.

主要方法:

文献综述侧重于LSD1/HDAC双位抑制剂的临床前和临床研究.
对报告的双抑制剂进行分析,以了解它们的疗效,选择性和毒性概况.
检查这些化合物的协同抗瘤作用背后的机制.

主要成果:

针对LSD1和HDAC的双功能抑制剂显示出协同的染色质重塑和增强的抗瘤作用.
几种双抑制剂已经显示出强大的瘤抑制,具有有利的毒性和选择性概况.
这些抑制剂是克服耐药性和补偿信号通路的有希望的策略.

结论:

双标LSD1/HDAC抑制剂为癌症治疗提供了一个新且有前途的方向.
需要进一步的研究来优化药理动力学,提高标选择性,并了解耐药性机制.
系统性验证对于这些先进治疗剂的成功临床转化至关重要.

关键词:

癌症治疗治疗癌症治疗双目标抑制剂的双目标抑制剂在HDAC的基础上,HDAC是一个LSD1一个LSD1

更多相关视频

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...